Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1

被引：73

作者：

Ballou, WR

Reed, JL

Noble, W

Young, NS

Koenig, S

机构：

[1] Medimmune Inc, Gaithersburg, MD 20878 USA

[2] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2003年 / 187卷 / 04期

关键词：

D O I：

10.1086/368382

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n = 24) received either 2.5 or 25 mug MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.

引用

页码：675 / 678

页数：4

共 15 条

[1] HUMAN PARVOVIRUS INFECTION IN PREGNANCY AND HYDROPS-FETALIS
ANAND, A
GRAY, ES
BROWN, T
CLEWLEY, JP
COHEN, BJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (04) : 183 - 186
[2] Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase polymerase chain reaction based assay
Bostic, JR
Brown, KE
Young, NS
Koenig, S
[J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (03) : 619 - 626
[3] MOLECULAR, CELLULAR AND CLINICAL ASPECTS OF PARVOVIRUS B19 INFECTION
BROWN, KE
YOUNG, NS
LIU, JM
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1994, 16 (01) : 1 - 31
[4] Chernoff D, 1995, VACCINE DESIGN SUBUN, P277
[5] KAIJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646
[6] HUMAN-SERUM PARVOVIRUS - A SPECIFIC CAUSE OF APLASTIC CRISIS IN CHILDREN WITH HEREDITARY SPHEROCYTOSIS
KELLEHER, JF
LUBAN, NLC
MORTIMER, PP
KAMIMURA, T
[J]. JOURNAL OF PEDIATRICS, 1983, 102 (05) : 720 - 722
[7] KOMATSU N, 1993, BLOOD, V82, P456
[8] Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
Nicholson, KG
Colegate, AE
Podda, A
Stephenson, I
Wood, J
Ypma, E
Zambon, MC
[J]. LANCET, 2001, 357 (9272) : 1937 - 1943
[9] A phase I/II trial of HIVSF2 gp120/MF59 vaccine in seronegative Thais
Nitayaphan, S
Khamboonruang, C
Sirisophana, N
Morgan, P
Chiu, J
Duliege, AM
Chuenchitra, C
Supapongse, T
Rungruengthanakit, K
deSouza, M
Mascola, JR
Boggio, K
Ratto-Kim, S
Markowitz, LE
Birx, D
Suriyanon, V
McNeil, JG
Brown, AE
Michael, RA
[J]. VACCINE, 2000, 18 (15) : 1448 - 1455
[10] NOVEL TRANSCRIPTION MAP FOR THE B19 (HUMAN) PATHOGENIC PARVOVIRUS
OZAWA, K
AYUB, J
HAO, YS
KURTZMAN, G
SHIMADA, T
YOUNG, N
[J]. JOURNAL OF VIROLOGY, 1987, 61 (08) : 2395 - 2406

← 1 2 →